MedTrace Logo

A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants

NCT04718636 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-10-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of CC-99677 coadministration on the pharmacokinetics (PK) of an oral contraceptive (OC).

Conditions

  • Healthy Volunteers

Interventions

DRUG

Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)

Daily

DRUG

CC-99677

Daily

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Kofi Mensah, MD, PhD · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-08-03
Completion
2021-08-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04718636 on ClinicalTrials.gov